USPHHealthcare · Medical Care FacilitiesThe 7 Wall Street analysts covering U.S. Physical Therapy, Inc. hold a median 12-month price target of $97 — +24.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores U.S. Physical Therapy, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (73): The share price has been relatively steady.
Quality (44): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Size (43): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on USPH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +24.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | Barrington Research | Maintains | Outperform | $90 → $98 |
| 24 June 2026 | Citizens | Reiterates | Market Outperform | $98 |
| 24 June 2026 | Citizens | Reiterates | Market Outperform | — |
| 13 May 2026 | Barrington Research | Maintains | Outperform | — |
| 8 May 2026 | Citizens | Maintains | Market Outperform | — |
| 10 Mar 2026 | Jefferies | Assumes | Buy | $102 |
| 20 Feb 2026 | Barrington Research | Maintains | Outperform | — |
| 5 Jan 2026 | Barrington Research | Maintains | Outperform | — |
| 24 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 24 Oct 2025 | Barrington Research | Maintains | Outperform | — |
| 18 Sept 2025 | JP Morgan | Assumes | Overweight | $110 |
| 8 Aug 2025 | Barrington Research | Maintains | Outperform | — |
| 1 July 2025 | Barrington Research | Maintains | Outperform | — |
| 22 Apr 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 19 Mar 2025 | JP Morgan | Maintains | Overweight | — |
| 28 Feb 2025 | Barrington Research | Maintains | Outperform | — |
| 16 Dec 2024 | B of A Securities | Upgrade | Buy | — |
| 16 Dec 2024 | JMP Securities | Initiates | Market Outperform | — |
| 3 Dec 2024 | JP Morgan | Maintains | Overweight | — |
| 21 Nov 2024 | Barrington Research | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. USPH appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 2% of US stocks
Cheaper than 61% of US stocks
Cheaper than 40% of US stocks
Cheaper than 18% of US stocks
Higher than 48% of US stocks
Higher than 20% of US stocks
Higher than 21% of US stocks
Higher than 66% of US stocks
Higher than 57% of US stocks
Higher than 56% of US stocks
Higher than 71% of US stocks
Higher than 52% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own U.S. Physical Therapy, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
U.S. Physical Therapy announced that Nchacha Etta will serve as Executive Vice President and Chief Financial Officer, effective September 1, 2026. Since April 24, 2026, Jason Curtis had served as Interim CFO.
Why it matters — A USPH watcher would care because the company has formally filled the CFO role, resolving interim leadership and setting future financial management direction.
U.S. Physical Therapy reported second-quarter 2026 revenue growth driven by higher patient volumes, improved reimbursement rates, and early rollout of hospital-affiliation agreements. However, elevated employee healthcare claims and upfront staffing costs pressured physical therapy margins.
Why it matters — USPH watchers would care because the quarter reflects both revenue growth drivers and margin pressures that could shape the company's near-term performance.
U.S. Physical Therapy, Inc. (USPH) released the transcript of its Q2 2026 earnings call, as published on Seeking Alpha. The document covers the company's second-quarter 2026 results discussion.
Why it matters — USPH watchers rely on the quarterly earnings call transcript for direct insight into the company's recent performance and management commentary.
U.S. Physical Therapy remains rated Hold as Q2 2026 revenue exceeded expectations but earnings per share fell short due to one-time events and rising costs. Clinic expansion, hospital affiliations, and industrial injury prevention services are driving top-line growth and future margin improvement.
Why it matters — USPH watchers would care because the company is balancing encouraging revenue growth and expansion initiatives against profitability shortfalls and a fair valuation that keeps the stock at a Hold rating.
U.S. Physical Therapy (USPH) reported second-quarter earnings of $0.75 per share, below the Zacks Consensus Estimate of $0.85 per share and down from $0.81 per share in the same period last year.
Why it matters — USPH watchers would note the earnings miss signals weaker-than-expected quarterly performance versus analyst forecasts and the prior-year period.
The 7 Wall Street analysts covering U.S. Physical Therapy, Inc. have a median 12-month price target of $97, with estimates ranging from $88 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering U.S. Physical Therapy, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks U.S. Physical Therapy, Inc. 51 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, U.S. Physical Therapy, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (73 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +24.2% from the last close, and Ticker Nerd's factor model ranks U.S. Physical Therapy, Inc. 51 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering U.S. Physical Therapy, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for USPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $88 to $100 over the next 12 months.
U.S. Physical Therapy, Inc. returned -5.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
U.S. Physical Therapy, Inc.
The most recent item we track (Business Wire, 14 Aug 2026): "U.S. Physical Therapy Announces CFO". U.S. Physical Therapy announced that Nchacha Etta will serve as Executive Vice President and Chief Financial Officer, effective September 1, 2026. Since April 24, 2026, Jason Curtis had served as Interim CFO.
U.S. Physical Therapy, Inc. is a healthcare services company that operates outpatient physical and occupational therapy clinics across the United States. The company focuses on rehabilitation and recovery care for orthopedic, sports-related, neurologic, and work-related injuries, serving patients who need pre-operative, post-operative, preventive, and restorative treatment. Its business also includes industrial injury prevention services that support employers with onsite ergonomics, injury reduction, functional testing, and return-to-work programs. Through a mix of owned and managed clinics, U.S. Physical Therapy works with local therapists, physicians, insurers, and employers to deliver specialized outpatient care and workplace health solutions. Founded in 1990 and headquartered in Houston, Texas, the company is recognized as a major pure-play provider in the outpatient therapy market.
CEO Mr. Christopher J. Reading · 4,653 employees · United States · https://www.usph.com